Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Share-based Compensation (2016 - 2025)

Traws Pharma (TRAW) has disclosed Share-based Compensation for 14 consecutive years, with $135000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 60.64% to $135000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $735000.0, a 47.05% decrease, with the full-year FY2024 number at $1.4 million, up 6.84% from a year prior.
  • Share-based Compensation was $135000.0 for Q3 2025 at Traws Pharma, up from $105000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $380000.0 in Q2 2024 to a low of $60000.0 in Q2 2021.
  • A 5-year average of $254736.8 and a median of $288000.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 355.38% in 2022, then tumbled 72.37% in 2025.
  • Traws Pharma's Share-based Compensation stood at $261000.0 in 2021, then skyrocketed by 32.95% to $347000.0 in 2022, then dropped by 4.32% to $332000.0 in 2023, then increased by 0.6% to $334000.0 in 2024, then crashed by 59.58% to $135000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Share-based Compensation are $135000.0 (Q3 2025), $105000.0 (Q2 2025), and $161000.0 (Q1 2025).